AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23254437 — intervention group
Group type: COMPARATOR
Intervention: Artesunate (200 mg dose followed by 100 mg/day for 6 days)
Number of subjects: 116
Study 22004768 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD risk assessment/communication + behavior change program (tailored website and individual coaching)
Number of subjects: 314
Study 22004768 — intervention group
Group type: COMPARATOR
Intervention: CVD risk assessment/communication
Number of subjects: 314
Study 19250367 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening induction (21:00 hours)
Number of subjects: 371
Study 19250367 — intervention group
Group type: COMPARATOR
Intervention: Morning induction (07:00 hours)
Number of subjects: 371
Study 16458259 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (sublingual administration, single dose)
Number of subjects: 20
Study 16458259 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 20
Study 15123479 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based care group (daily inhaled corticosteroids provided through the school)
Number of subjects: 184
Study 15123479 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based care group
Number of subjects: 184
Study 15123479 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based care group (among children not exposed to secondhand smoke)
Number of subjects: 184
Study 12141848 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive problem-based educational program (I)
Number of subjects: 0
Study 12141848 — intervention group
Group type: COMPARATOR
Intervention: Lecture-style educational program (L)
Number of subjects: 0
Study 12141848 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (I and L)
Number of subjects: 0
Study 9450159 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivagabine 1800 mg/d for four weeks
Number of subjects: 118
Study 9450159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 7949496 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent bolus famotidine (50 mg/24 h, 25th‐75th percentiles = 40‐55 mg)
Number of subjects: 20
Study 7949496 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion famotidine (42 mg/24 h, 25th‐75th percentiles = 42‐52 mg)
Number of subjects: 20
Study 3070612 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate infusion
Number of subjects: 21
Study 3070612 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol infusion
Number of subjects: 21
Study 3070612 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 21
Study 31836930 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab 300 mg at Weeks 0, 2, and 6 (induction phase)
Number of subjects: 157
Study 31836930 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab 300 mg at Week 14 and every 8 weeks until Week 54 (maintenance phase)
Number of subjects: 157
Study 31836930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study 28510773 — intervention group
Group type: EXPERIMENTAL
Intervention: Video game play plus occlusion therapy (1 hour of video game play per day for the first month plus 6 hours of occlusion therapy per day)
Number of subjects: 68
Study 28510773 — intervention group
Group type: COMPARATOR
Intervention: Occlusion therapy alone (6 hours per day)
Number of subjects: 68
Study 28510773 — intervention group
Group type: COMPARATOR
Intervention: Comparison between video game and occlusion group and occlusion only group
Number of subjects: 68
Study 26077603 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch (6 weeks)
Number of subjects: 269
Study 26077603 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral counseling (3 in-person sessions + 5 follow-up phone sessions)
Number of subjects: 269
Study 26077603 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch (6 weeks)
Number of subjects: 269
Study 26077603 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral treatment
Number of subjects: 269
Study 26077603 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological treatment
Number of subjects: 269
Study 23700731 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose daily de-escalatory administration of tadalafil for 2 months
Number of subjects: 84
Study 23700731 — intervention group
Group type: COMPARATOR
Intervention: On-demand medication of tadalafil for 2 months
Number of subjects: 84
Study 20416893 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 25 mg orally, 3 times daily for 7 days preoperatively
Number of subjects: 85
Study 20416893 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving oral placebo
Number of subjects: 85
Study 19095497 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib (400 mg orally twice daily)
Number of subjects: 271
Study 19095497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 271
Study 17100936 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil
Number of subjects: 260
Study 17100936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study 15304144 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in shared decision making (SDM) or combined with risk communication (RC)
Number of subjects: 0
Study 15304144 — intervention group
Group type: COMPARATOR
Intervention: Risk communication (RC)
Number of subjects: 0
Study 15304144 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in SDM or combined with RC
Number of subjects: 0
Study 11776507 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 microg estradiol vaginal tablet
Number of subjects: 53
Study 11776507 — intervention group
Group type: COMPARATOR
Intervention: 1 g conjugated estrogen cream
Number of subjects: 53
Study 11776507 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 53
Study 9603794 — intervention group
Group type: EXPERIMENTAL
Intervention: Goggles reducing visible-light exposure by 97% and ultraviolet-light exposure by 100%
Number of subjects: 409
Study 9603794 — intervention group
Group type: COMPARATOR
Intervention: Typical nursery lighting (control group)
Number of subjects: 409
Study 8090608 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta 2-agonist (terbutaline, 500 micrograms via nebuhaler)
Number of subjects: 10
Study 8090608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8090608 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta 2-agonist (terbutaline)
Number of subjects: 10
Study 2899772 — intervention group
Group type: EXPERIMENTAL
Intervention: 1‐hour intravenous infusion of 1.5 MU of streptokinase
Number of subjects: 17187
Study 2899772 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg/day enteric‐coated aspirin for one month
Number of subjects: 17187
Study 2899772 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of streptokinase and aspirin
Number of subjects: 17187
Study 2899772 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase alone
Number of subjects: 17187
Study 2899772 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin alone
Number of subjects: 17187
Study 2899772 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 17187
Study 2899772 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 17187
Study 2899772 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase and aspirin
Number of subjects: 17187
Study 30746695 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-sectional approaches using HIV diagnostic tests and biomarkers of recent infection
Number of subjects: 0
Study 30746695 — intervention group
Group type: EXPERIMENTAL
Intervention: Random effects model to account for heterogeneity
Number of subjects: 0
Study 30746695 — intervention group
Group type: EXPERIMENTAL
Intervention: Permutation test for null hypothesis of no heterogeneity
Number of subjects: 0
Study 28112800 — intervention group
Group type: EXPERIMENTAL
Intervention: iPad version of the Dermatology Life Quality Index (DLQI)
Number of subjects: 104
Study 28112800 — intervention group
Group type: COMPARATOR
Intervention: Paper version of the Dermatology Life Quality Index (DLQI)
Number of subjects: 104
Study 25900704 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced spectral mammography (CESM)
Number of subjects: 49
Study 25900704 — intervention group
Group type: COMPARATOR
Intervention: Contrast-enhanced MRI (CEMRI)
Number of subjects: 49
Study 23358966 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 492
Study 23358966 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized dosing of EC‐Asnase (ID)
Number of subjects: 492
Study 23358966 — intervention group
Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 492
Study 23358966 — intervention group
Group type: COMPARATOR
Intervention: Fixed dosing of EC‐Asnase (FD)
Number of subjects: 492
Study 22155904 — intervention group
Group type: EXPERIMENTAL
Intervention: Valganciclovir (900 mg once daily)
Number of subjects: 36
Study 22155904 — intervention group
Group type: COMPARATOR
Intervention: Valacyclovir (2 g four times daily)
Number of subjects: 36
Study 19301011 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary electronically cleansed 3D
Number of subjects: 72
Study 19301011 — intervention group
Group type: COMPARATOR
Intervention: Primary uncleansed 2D
Number of subjects: 72
Study 16845914 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 102
Study 16845914 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 102
Study 15295326 — intervention group
Group type: EXPERIMENTAL
Intervention: stainless steel dowels (ParaPost)
Number of subjects: 41
Study 15295326 — intervention group
Group type: EXPERIMENTAL
Intervention: glass fiber dowels (Snowpost)
Number of subjects: 41
Study 15295326 — intervention group
Group type: EXPERIMENTAL
Intervention: resin‐supported polyethylene fiber (Ribbond) dowels
Number of subjects: 41
Study 15295326 — intervention group
Group type: EXPERIMENTAL
Intervention: zirconia dowels (Cosmopost)
Number of subjects: 41
Study 14676767 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline mixed with calcium hydroxide (CH)
Number of subjects: 55
Study 14676767 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin mixed with calcium hydroxide (CH)
Number of subjects: 55
Study 10994883 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous passive motion (CPM) for 5 consecutive hours per day plus physical therapy
Number of subjects: 51
Study 10994883 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy only
Number of subjects: 51
Study 8793703 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonists or angiotensin converting enzyme inhibitors (n = 266)
Number of subjects: 382
Study 8793703 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration (n = 116)
Number of subjects: 382
Study 1465059 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal protein diet (1.1 +/- 0.3 g/kg/day)
Number of subjects: 44
Study 1465059 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet (0.7 +/- 0.1 g/kg/day)
Number of subjects: 44
Study 1465059 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary manipulation (low-protein and normal protein diets)
Number of subjects: 44
Study 1465059 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetarian soy diet (0.71 +/- 0.36 g/kg ideal body weight/day)
Number of subjects: 44
Study 1465059 — intervention group
Group type: COMPARATOR
Intervention: Free diet (baseline control period)
Number of subjects: 44
Study 3871797 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated erythromycin pellets (250 mg base)
Number of subjects: 24
Study 3871797 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin ethylsuccinate (400 mg base equivalent)
Number of subjects: 24
Study 3622938 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (20 mg p.o.)
Number of subjects: 9
Study 3622938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 31232853 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic needle tip positioning (n = 30)
Number of subjects: 60
Study 31232853 — intervention group
Group type: COMPARATOR
Intervention: Static group (n = 30)
Number of subjects: 60
Study 28719580 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin (INI)
Number of subjects: 0
Study 28719580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25978046 — intervention group
Group type: EXPERIMENTAL
Intervention: Melissa officinalis extract containing 500 mg rosmarinic acid (fasted state)
Number of subjects: 11
Study 25978046 — intervention group
Group type: EXPERIMENTAL
Intervention: Melissa officinalis extract containing 500 mg rosmarinic acid (fed state)
Number of subjects: 11
Study 25978046 — intervention group
Group type: EXPERIMENTAL
Intervention: Melissa officinalis extract containing 500 mg rosmarinic acid
Number of subjects: 11
Study 23911602 — intervention group
Group type: EXPERIMENTAL
Intervention: Omission of secondary casts obtained from impressions in border moulded custom trays (Group 1)
Number of subjects: 43
Study 23911602 — intervention group
Group type: EXPERIMENTAL
Intervention: Omission of secondary casts and face-bow articulator mounting (Group 2)
Number of subjects: 43
Study 23911602 — intervention group
Group type: EXPERIMENTAL
Intervention: Omission of face-bow mounting (Group 3)
Number of subjects: 43
Study 23911602 — intervention group
Group type: COMPARATOR
Intervention: No steps omitted (control, Group 4)
Number of subjects: 43
Study 21739499 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone pessaries from 20-24 weeks until 34 weeks' gestation
Number of subjects: 72
Study 21739499 — intervention group
Group type: COMPARATOR
Intervention: Placebo pessaries from 20-24 weeks until 34 weeks' gestation
Number of subjects: 72
Study 21739499 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone pessaries
Number of subjects: 72
Study 21739499 — intervention group
Group type: COMPARATOR
Intervention: Placebo pessaries
Number of subjects: 72
Study 19114860 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring (TDM) with protease inhibitor dose escalation
Number of subjects: 183
Study 19114860 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 183
Study 16764552 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed Up and Go Test (TUG) completion
Number of subjects: 2463
Study 16764552 — intervention group
Group type: COMPARATOR
Intervention: Other significant predictors
Number of subjects: 2463
Study 15663123 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate solution (25 g carbohydrates)
Number of subjects: 202
Study 15663123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study 11510870 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuous training protocol (25 times 80 s at 35% VO2max and 40 s at 80% VO2max)
Number of subjects: 14
Study 11510870 — intervention group
Group type: COMPARATOR
Intervention: Continuous training protocol (50 min at 50% VO2max)
Number of subjects: 14
Study 9150807 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) monotherapy
Number of subjects: 26
Study 9150807 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (VGB) add-on treatment
Number of subjects: 26
Study 9150807 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 26
Study 7919566 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrine (cholinesterase inhibitor)
Number of subjects: 0
Study 3585450 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release morphine sulfate (MSC)
Number of subjects: 0
Study 3585450 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release morphine sulfate (IRMS)
Number of subjects: 0
Study 31843338 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (182 patients)
Number of subjects: 458
Study 31843338 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (178 patients)
Number of subjects: 458
Study 31843338 — intervention group
Group type: COMPARATOR
Intervention: Standard radiotherapy (108 patients)
Number of subjects: 458
Study 31843338 — intervention group
Group type: COMPARATOR
Intervention: Reduced high‐dose volume radiotherapy (111 patients)
Number of subjects: 458
Study 30989173 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmentor software package for image augmentation
Number of subjects: 0
Study 27900942 — intervention group
Group type: EXPERIMENTAL
Intervention: GFR < 45 mL/min/1.73 m2
Number of subjects: 2338
Study 27900942 — intervention group
Group type: COMPARATOR
Intervention: GFR ≥ 90 mL/min/1.73 m2
Number of subjects: 2338
Study 26322635 — intervention group
Group type: EXPERIMENTAL
Intervention: 30‐mL balloon for a maximum of 12 hours
Number of subjects: 504
Study 26322635 — intervention group
Group type: EXPERIMENTAL
Intervention: 30‐mL balloon for a maximum of 24 hours
Number of subjects: 504
Study 26322635 — intervention group
Group type: EXPERIMENTAL
Intervention: 80‐mL balloon for a maximum of 12 hours
Number of subjects: 504
Study 26322635 — intervention group
Group type: EXPERIMENTAL
Intervention: 80‐mL balloon for a maximum of 24 hours
Number of subjects: 504
Study 26322635 — intervention group
Group type: COMPARATOR
Intervention: 12-hour Foley catheter groups
Number of subjects: 504
Study 26322635 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 504
Study 26322635 — intervention group
Group type: COMPARATOR
Intervention: Higher balloon volume (80‐mL) and longer ripening time (24 hours)
Number of subjects: 504
Study 23237821 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced home visiting program
Number of subjects: 8080
Study 23237821 — intervention group
Group type: COMPARATOR
Intervention: Standard home visiting program
Number of subjects: 8080
Study 22016915 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Easy Bond (AEB)
Number of subjects: 30
Study 22016915 — intervention group
Group type: EXPERIMENTAL
Intervention: AEB + Hydrophobic Resin (HR)
Number of subjects: 30
Study 22016915 — intervention group
Group type: EXPERIMENTAL
Intervention: Etch + AEB
Number of subjects: 30
Study 22016915 — intervention group
Group type: EXPERIMENTAL
Intervention: Etch + AEB + HR
Number of subjects: 30
Study 22016915 — intervention group
Group type: COMPARATOR
Intervention: Adper Single Bond Plus (ASB)
Number of subjects: 30
Study 22016915 — intervention group
Group type: COMPARATOR
Intervention: Adper Scotchbond Multi-Purpose (SBMP)
Number of subjects: 30
Study 22016915 — intervention group
Group type: EXPERIMENTAL
Intervention: AEB
Number of subjects: 30
Study 22016915 — intervention group
Group type: EXPERIMENTAL
Intervention: AEB + HR
Number of subjects: 30
Study 22016915 — intervention group
Group type: COMPARATOR
Intervention: ASB
Number of subjects: 30
Study 22016915 — intervention group
Group type: COMPARATOR
Intervention: SBMP
Number of subjects: 30
Study 18556090 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose
Number of subjects: 0
Study 18556090 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharin
Number of subjects: 0
Study 18556090 — intervention group
Group type: COMPARATOR
Intervention: Acetic acid
Number of subjects: 0
Study 18556090 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride
Number of subjects: 0
Study 18556090 — intervention group
Group type: COMPARATOR
Intervention: Quinine hydrochloride
Number of subjects: 0
Study 18556090 — intervention group
Group type: COMPARATOR
Intervention: Distilled water
Number of subjects: 0
Study 18556090 — intervention group
Group type: COMPARATOR
Intervention: Starch
Number of subjects: 0
Study 18556090 — intervention group
Group type: COMPARATOR
Intervention: Sodium glutamate
Number of subjects: 0
Study 16879332 — intervention group
Group type: EXPERIMENTAL
Intervention: Wand (computerized device)
Number of subjects: 138
Study 16879332 — intervention group
Group type: COMPARATOR
Intervention: Conventional buccal infiltration (CBi)
Number of subjects: 138
Study 16879332 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal ligament injection (PDLi)
Number of subjects: 138
Study 16879332 — intervention group
Group type: EXPERIMENTAL
Intervention: Palatal approach-anterior superior alveolar (P-ASA) nerve block
Number of subjects: 138
Study 12586320 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol alone
Number of subjects: 0
Study 12586320 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol with diclofenac sodium (NSAID)
Number of subjects: 0
Study 11421896 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium, two puffs twice daily, 0.002 g/puff
Number of subjects: 39
Study 11421896 — intervention group
Group type: COMPARATOR
Intervention: Placebo, two puffs twice daily
Number of subjects: 39
Study 9508754 — intervention group
Group type: EXPERIMENTAL
Intervention: Diacarb administered after the proposed protocols
Number of subjects: 130
Study 8514653 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily dosing of netilmicin (6 mg/kg body weight)
Number of subjects: 116
Study 8514653 — intervention group
Group type: COMPARATOR
Intervention: Thrice-daily dosing of netilmicin (6 mg/kg body weight)
Number of subjects: 116
Study 8514653 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily dosing of netilmicin
Number of subjects: 116
Study 8514653 — intervention group
Group type: COMPARATOR
Intervention: Thrice-daily dosing of netilmicin
Number of subjects: 116
Study 3734289 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 2.2 or 4.4 mg of azelastine
Number of subjects: 20
Study 3734289 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple dose therapy with 4.4 mg of azelastine for 21 days
Number of subjects: 20
Study 3734289 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 20
Study 30531384 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐dopa ON
Number of subjects: 27
Study 30531384 — intervention group
Group type: COMPARATOR
Intervention: L‐dopa OFF
Number of subjects: 27
Study 30531384 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice dose and acquisition rate
Number of subjects: 27
Study 30531384 — intervention group
Group type: EXPERIMENTAL
Intervention: Plateau during practice
Number of subjects: 27
Study 28205481 — intervention group
Group type: EXPERIMENTAL
Intervention: 6‐0 Prolene
Number of subjects: 16
Study 28205481 — intervention group
Group type: COMPARATOR
Intervention: 6‐0 Nylon
Number of subjects: 16
Study 28205481 — intervention group
Group type: EXPERIMENTAL
Intervention: Both sutures (Prolene and Nylon)
Number of subjects: 16